# US 2009/0270447 A1 · 2-Aryl-and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270447 A1
- Document ID: US20090270447A1
- Status: Published application
- Kind: A1
- Application number: 12/412,538
- Filed: 2009-03-27
- Published: 2009-10-29
- Earliest claimed: 2008-03-27
- Assignees: Wyeth
- Inventors: Nan Zhang; Semiramis Ayral-Kaloustian; Thai Hiep Nguyen; Chuansheng Niu; Edward Christian Rosfjord; Ronald Suayan
- Web page: https://patentgrep.com/patent/US20090270447A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses fused heterobicyclic 2-aryl- and 2-heteroarylthiazolyl compounds and their pharmaceutically acceptable salts and esters thereof, which are useful for inhibiting the growth of cancerous cells, inhibiting human breast carcinoma tumor growth in particular and to treat diseases or disorders associated with securin.

## Claims

### Claim 1

A compounds of formula I:
and pharmaceutically acceptable salts thereof,
wherein
A is H, C1-C3 alkyl, or acetyl;
Z is NR3 or O;
Q is —NR1R2, —NR3N(R3)2, —NR3OR3, or —OH;
R1 and R2 are each independently H or C1-C3 alkyl, or R1 and R2 join together with the nitrogen atom to which each is attached, forming a 4 to 6 membered saturated heterocyclic ring comprising heteroatoms selected from 1-2 nitrogen atoms, 0-1 oxygen atom and 0-1 sulfur atom, said ring optionally substituted with one or more of R4;
R3 at each occurrence is independently H or C1-C3 alkyl;
R4 is C1-C3 alkyl, —N(R3)2, or —OH;
Y1, Y2, Y3, and Y4 are the same or different, and are each independently N or CR5, or two R5 groups on adjacent carbon atoms join together, with the carbon atoms which they are bonded, to form a 9 to 10 membered bicyclic aryl ring or bicyclic heteroaryl ring, said ring comprising members selected from CR5 and N;
R5 is independently H or is independently selected from C1-C3 alkyl, F, Cl, Br, I, CF3, NO2, —NR1R2, —CHO, —CONHAr, —C(R3)2OR3, —C(R3)2O[C(R3)2]Ar, —C(R3)2NR1R2, —C(R3)2NR3[C(R3)2]2NR1R2, —CO2R6, —SOR6, and —SO2R6, where Ar is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 2-furyl, or 3-furyl, optionally substituted with one or more of R4;
R6 is independently H or is independently selected from C1-C8 alkyl, C2-C8 alkenyl, and C2-C8 alkynyl, each optionally substituted with —NR1R2, —OR3, C4-C6 cycloalkyl, a saturated heterocyclic ring comprising heteroatoms selected from 0-1 nitrogen atom, 0-1 oxygen atom and 0-1 sulfur atom, or —COCH3, C4-C6 cycloalkyl, optionally substituted with R4; or a saturated heterocyclic ring comprising heteroatoms selected from 0-1 nitrogen atom, 0-1 oxygen atom and 0-1 sulfur atom, and optionally substituted with one or more of R4; and
m is 0 or 1.

### Claim 2 (depends on 1)

The compound of claim 1, wherein m is 0, A is H and Z is NR3.

### Claim 3 (depends on 1)

The compound of claim 1, wherein m is 0, A is H and Z is O.

### Claim 4 (depends on 1)

The compound of claim 1, wherein m is 0, A is H and Z is NH.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of one of claims 1-4, wherein the ring formed by Y1, Y2, Y3, and Y4 is selected from: phenyl, pyridinyl, pyrimidinyl, and pyrazinyl.

### Claim 6 (depends on 1, 2, 3, 4)

The compound of one of claims 1-4, wherein Y1 and Y2 or Y3 and Y4 are CR5 and the two R5 groups on adjacent carbon atoms join together, with the carbon atoms which they are bonded, to form a 9 to 10 membered bicyclic aryl ring or bicyclic heteroaryl ring selected from: napthyl, indenyl, indolyl, benzoxazolyl, benzothiazolyl, benzofuranyl, benzisoxazolyl, benzimidazolyl, N-methylbenzimidazolyl, azabenzimidazolyl, indazolyl, quinazolinyl, quinolinyl and isoquinolinyl.

### Claim 7

A compound selected from:
and pharmaceutically acceptable salts thereof.

### Claim 8

A compound selected from: 2-(4-dimethylamino-phenyl)-5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridine-7-ol, (R,S)-2-(4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (R)-2-(4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (S)-2-(4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R,S)-2-(4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R)-2-(4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7S)-2-(4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, 2-(2-hydroxymethyl-4-dimethylamino-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridine-7-ol, methyl 5-(dimethylamino)-2-(7-hydroxy-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridine-2-yl)benzoate, (7R,7S)-2-(2-hydroxymethyl-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R)-2-(2-hydroxymethyl-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, (7R,7S)-2-(2-hydroxymethyl-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, methyl 5-(4-pyrrolidin-1-yl)-2-(7-hydroxy-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-2-yl)benzoate, 2-(2-amino-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, 2-(2-nitro-4-pyrrolidin-1-yl-phenyl)-4,5,6,7-tetrahydro[1,3]thiazolo[4,5-c]pyridin-7-ol, 2-[3-bromo-4-(dimethylamino)phenyl]-6,7-dihydro-4H-pyrano[3,4-d][1,3]thiazol-7-ol, 2-[4-(dimethylamino)phenyl]-6,7-dihydro-4H-pyrano[3,4-d][1,3]thiazol-7-ol and pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutically acceptable ester of a compound of claims 1-8.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition comprising a compound of one of claims 1-9 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

A method for preparing a compound of claim 1, comprising the steps of:
(a) reacting a compound of formula 2:
with tert-butyl 5-oxo-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate, thereby forming a compound of formula 3:
(b) treating the compound of formula 3 formed in step (a) with an acid,
wherein A is H.

### Claim 12 (depends on 1)

A method for preparing a compound of claim 1, comprising the steps of:
(a) cyclizing a compound of formula 8:
thereby forming a compound of formula 9:
(b) treating the compound of formula 9 formed in step (f) with a reducing agent (sodium borohydride), thereby forming a compound of formula 10:
(c) treating the compound of formula 10 formed in step (b) with a deprotecting agent.

### Claim 13 (depends on 1)

A method for preparing a compound of claim 1, comprising the steps of:
(a) cyclizing a compound of formula 7:
thereby forming a compound of formula 9:
(b) treating the compound of formula 9 formed in step (a) with a reducing agent.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for treating a disease associated with securin comprising administering to a subject in need a therapeutically effective amount of a compound of any one of claims 1-9.

### Claim 15 (depends on 14)

The method of claim 14, wherein the therapeutically effective amount is from 0.1 mg/kg/day to 1000 mg/kg/day.

### Claim 16 (depends on 14, 15)

The method of claim 14 or 15, wherein the disease associated with securin is a cancer selected from: breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin, thyroid, prostate and brain cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is breast cancer.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for inhibiting tumor growth in a subject comprising administering to a subject in need a therapeutically effective amount of a compound any one of claims 1-9.

### Claim 19 (depends on 18, 19)

The method of claim 18 or 19, wherein tumor growth is associated with a cancer selected from: breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin, thyroid, prostate and brain cancer.

### Claim 20 (depends on 18)

The method of claim 18, wherein the therapeutically effective amount is from 0.1 mg/kg/day to 1000 mg/kg/day.

### Claim 21 (depends on 18)

The method of claim 18, wherein tumor growth is associated with a human breast carcinoma.

### Claim 22 (depends on 1, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 14-21, wherein a chemotherapeutic agent is used in combination with the therapeutically effective amount of a compound of claim 1.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition comprising a compound of any one of claims 1-9 in combination with another kinase-inhibiting compound or chemotherapeutic agent, and a pharmaceutically acceptable carrier.
